Connect
MJA
MJA

Multidrug-resistant tuberculosis in Australia and our region

James M Trauer and Allen C Cheng
Med J Aust 2016; 204 (7): 251-253. || doi: 10.5694/mja16.00012

MDR-TB threatens TB control programs in Australia’s region and will not diminish without concerted efforts

Tuberculosis (TB) is one of the world’s great killers, but Australia has been relatively protected because of its strong public health system. Of 1300 cases reported in Australia each year, almost 90% occur in the overseas born, although Indigenous Australians are also disproportionately affected. Most cases arise in the large immigrant communities from India, Vietnam, the Philippines, China and Nepal, but high rates are also reported from Papua New Guinea (PNG), Ethiopia, Somalia and Myanmar. These cases occur primarily in permanent residents and students, rather than in refugees or those on humanitarian visas.1

Please login with your free MJA account to view this article in full

  • James M Trauer1
  • Allen C Cheng1,2

  • 1 Monash University
  • 2 Alfred Health, Melbourne, VIC


Acknowledgements: 

Allen Cheng is supported by a National Health and Medical Research Council Career Development Fellowship.

Competing interests:

No relevant disclosures.

  • 1. Toms C, Stapledon R, Waring J, Douglas P, National Tuberculosis Advisory Committee. Tuberculosis notifications in Australia, 2012 and 2013. Commun Dis Intell 2015; 39: E217-E235. https://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3902-pdf-cnt.htm/$FILE/cdi3902f.pdf (accessed Mar 2016).
  • 2. World Health Organization. Global tuberculosis report 2015. http://www.who.int/tb/publications/global_report/gtbr15_main_text.pdf?ua=1 (accessed Mar 2016).
  • 3. McBryde ES. Evaluation of risks of tuberculosis in Western Province Papua New Guinea. Melbourne: Burnet Institute, 2012.
  • 4. Kirby T. Extensively drug-resistant tuberculosis hovers threateningly at Australia’s door. Med J Aust 2013; 198: 355. <MJA full text>
  • 5. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
  • 6. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
  • 7. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
  • 8. Marks SM, Flood J, Seaworth B, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis 2014; 20: 812-821.
  • 9. Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med 2015; 3: 963-972.
  • 10. Trauer JM, Denholm JT, Waseem S, Ragonnet R, McBryde ES. Scenario analysis for programmatic tuberculosis control in Western Province, Papua New Guinea. Am J Epidemiol 2015. In press.
  • 11. US Government. National action plan for combating multidrug-resistant tuberculosis: Washington, DC: The White House, 2015. https://www.whitehouse.gov/sites/default/files/microsites/ostp/national_action_plan_for_tuberculosis_20151204_final.pdf (accessed Mar 2016).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.